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Background: Neurobeachin (NBEA) has been identified as a candidate gene for autism spectrum disorders (ASD) in
several unrelated patients with alterations in the NBEA gene. The exact function of NBEA, a multidomain scaffolding
protein, is currently unknown. It contains an A-kinase anchoring protein (AKAP) domain which binds the regulatory
subunit of protein kinase A (PKA) thereby confining its activity to specific subcellular regions. NBEA has been
implicated in post-Golgi membrane trafficking and in regulated secretion. The mechanism of regulated secretion is
largely conserved between neurons and platelets, and the morphology of platelet dense granules was found to be
abnormal in several ASD patients, including one with NBEA haploinsufficiency. Platelet dense granules are secreted
upon vascular injury when platelets are exposed to for instance collagen. Dense granules contain serotonin, ATP
and ADP, which are necessary for platelet plug formation and vascular contraction.
Methods: To further investigate possible roles for NBEA in secretion or dense granule morphology, platelets from
Nbea+/− mice were analyzed morphometrically, functionally and biochemically. A differential proteomics and
peptidomics screen was performed between Nbea+/− and Nbea+/+ mice, in which altered Talin-1 cleavage was further
investigated and validated in brain samples. Finally, the phosphorylation pattern of PKA substrates was analyzed.
Results: Platelet dense granules of Nbea+/− mice had a reduced surface area and abnormal dense-core halo, but
normal serotonin-content. Nbea haploinsufficiency did not affect platelet aggregation and ATP secretion after collagen
stimulation, although the platelet shape change was more pronounced. Furthermore, peptidomics revealed that
Nbea+/− platelets contain significantly reduced levels of several actin-interacting peptides. Decreased levels were
detected of the actin-binding head and rod domain of Talin-1, which are cleavage products of Calpain-2. This is most
likely due to increased PKA-mediated phosphorylation of Calpain-2, which renders the enzyme less active. Analysis of
other PKA substrates revealed both increased and reduced phosphorylation.
Conclusion: Our results show the pleiotropic effects of alterations in PKA activity due to Nbea haploinsufficiency,
highlighting the important function of the AKAP domain in Nbea in regulating and confining PKA activity. Furthermore,
these results suggest a role for Nbea in remodeling the actin cytoskeleton of platelets.
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The genetic architecture of autism spectrum disorders
(ASDs) is highly heterogeneous and to date more than 100
genes have been reported to be deleted, duplicated, mu-
tated or disrupted by a translocation breakpoint in ASD
patients [1,2]. One of these candidate genes, Neurobeachin
(NBEA) [MIM: 604889] was identified in a patient with a
de novo balanced chromosomal translocation t(5;13)(q12.1;
q13.2) with one breakpoint in intron 2 of NBEA resulting
in a NBEA haploinsufficient status [3]. Additionally, four
unrelated ASD patients with a monoallelic deletion of
NBEA were reported [4-7], and three novel CNVs were de-
tected within the NBEA gene in three unrelated individuals
diagnosed with ASD [8-10]. Moreover, a single nucleotide
polymorphism (SNP) in intron 38 of NBEA has been asso-
ciated with ASD [11]. The NBEA gene contains a low-
frequency common fragile site (FRA13) linked to ASD and
is located in a 19 cM region identified as a candidate region
for ASD by a linkage study (MMLS/het score of 2.3 be-
tween markers D13S217 at 17.21 cM and D13S1229 at
21.51 cM) [12-14].
NBEA, a brain-enriched multidomain scaffolding pro-
tein, is located at the tubulovesicular endomembranes near
the trans-Golgi network [15,16]. The N-terminal region
contains a Concanavalin A-like lectin domain flanked by
armadillo repeats suggested to play a role in intracellular
trafficking [17,18]. Distal from these regions, an A-kinase
anchoring protein (AKAP) domain is present, recruiting
cAMP-dependent protein kinase A (PKA) by high-affinity
binding to its regulatory RIIα subunit [16]. The C-terminal
part of NBEA possesses a pleckstrin homology - beige and
Chediak-Higashi (BEACH) - WD40 domain module which
is thought to be implicated in vesicle trafficking [16,19].
NBEA and eight other human proteins contain the highly
conserved BEACH domain, and thus belong to the family
of BEACH proteins [20].
Although the exact function of NBEA is currently un-
known, a complete loss of Nbea in mice leads to a perinatal
lethal phenotype due to a complete block of evoked neuro-
muscular transmission [21]. By studying neuronal cultures
derived from E18 Nbea−/− mice, a role emerges for Nbea
in trafficking important cargo to pre- and postsynaptic
compartments, as these cultures have shown abnormal
large clusters of actin in the soma, dendritic shafts and
axons, and a reduced level of neurotransmitter receptors
has been detected at the surface of the postsynaptic mem-
brane [22,23]. Moreover, knockdown of Nbea in a neuro-
endocrine cell line (βTC3 cells) leads to enhanced
secretion of dense-core secretory granules, the neuroendo-
crine counterpart of large dense-core vesicles (LDCVs) in
neurons, making Nbea a negative regulator of the regulated
secretion [24].
Blood platelets are the first players to be activated upon
vascular injury. They are essential for initiating plateletplug formation and do so by secreting the content of their
secretory granules. Similar to neurons, platelets contain
two types of secretory granules, namely the alpha and
dense granules, corresponding to the small synaptic vesi-
cles (SVs) and LDCVs in neurons, respectively [25]. Blood
platelet alpha granules have a heterogeneous cargo of poly-
peptides ranging from adhesion molecules to growth fac-
tors, whereas dense granules contain the small molecules
ATP, ADP and serotonin, necessary for vasoconstriction.
Due to the similar regulation of granule formation and
transport, platelets were put forward as a model system to
study the biology of granule formation, trafficking and se-
cretion in neurons [26,27]. Preliminary in vivo analysis un-
veiled an abnormal morphology of the dense granules in
platelets of our reported patient with a chromosomal trans-
location in NBEA [24]. Moreover, similar platelet granule
abnormalities were observed in ASD patients with chromo-
somal rearrangements in Amisyn or SCAMP5, and in an
ASD patient with a deletion including SHANK3 [24]. Inter-
estingly, mutations in LYST and NBEA-like 2 (NBEAL2),
two other BEACH proteins, are described in patients with
Chediak-Higashi and Gray platelet syndrome and result in
abnormal to absent platelet dense and alpha granules, re-
spectively [28,29].
As platelets can easily be obtained from patients, further
insights into platelet abnormalities might lead to the identi-
fication of biomarkers associated with ASD. We have char-
acterized platelets from mice heterozygous for Nbea to
substantiate the causality of NBEA haploinsufficiency for
the abnormal platelet phenotype. The ultrastructure of the
dense granules of murine platelets was analyzed and plate-
let function was investigated. Moreover, serotonin levels
were determined in both serum and platelets, as hypersero-
tonemia is the only biochemical anomaly reported in
approximately 30% of ASD patients. Serotonin is a hor-
mone and monoamine neurotransmitter that can induce
vasoconstriction and is implicated in neuron outgrowth,
maturation, function and plasticity. It is synthesized in sero-
tonergic neurons of the central nervous system and in the
intestine, and more than 99% of whole blood serotonin is
stored in blood platelets [30]. To assess whether Nbea hap-
loinsufficiency affects the protein and peptide content of
platelets, a full proteomic and peptidomic analysis was per-
formed and results were further validated in platelets and
in total brain.
Methods
All experiments were approved by the ethical research
committee of KU Leuven in accordance with the declar-
ation of Helsinki (project number P182/2011).
Animals
The GH240B transgenic line described in Su et al. [21]
was backcrossed for at least 10 generations with C57BL/
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tained from adult (12-week-old) female mice.
Brains were dissected from 12-week-old mice and imme-
diately put at -80°C. Tissue was homogenized in sucrose
buffer (3.18 mM sucrose; 4 mM Tris–HCl pH 7.4) contain-
ing a protease and phosphatase inhibitor cocktail and a
complete protease inhibitor cocktail (both from Roche
Applied Science, Penzberg, Germany).
Platelet function analysis and platelet counts
Murine blood was anticoagulated with 3.2% trisodium
citrate (9:1) and mean platelet volume (MPV) and platelet
count were determined on an automated cell counter
(Cell-Dyn 1300 Abbott laboratories, Abbott Park, IL,
USA). Platelet-rich plasma (PRP) was obtained after centri-
fugation at 3,000 rpm for 30 sec followed by 800 rpm for 5
minutes. The platelet count was adjusted to 250,000 plate-
lets/μl with autologous plasma. Platelet aggregation and se-
cretion were performed as described after stimulation with
Horm collagen (5 μg/ml) [31,32]. Platelet secretion was de-
termined by measuring the release of ATP using luciferin/
luciferase reagent (Kordia, Leiden, The Netherlands). Elec-
tron microscopy analysis of murine platelets was per-
formed as previously reported [33]. Additional ultra-thin
sections of 50 to 70 nm were cut, stained with uranyl acet-
ate and lead citrate, and examined at 80 kV using a
JEM1400 transmission electron microscope (JEOL, Tokyo,
Japan). Micrographs were acquired on an SIS Quemesa
camera (Olympus, Münster, Germany). The number of
dense granules per platelet and dense granule dimension
and morphology were further assessed with the ImageJ im-
aging system (National Institutes of Health, Bethesda, MD,
USA) (n = 200 platelets/genotype). Dense granules were
classified as different types: type 1, solid core occupying
more than 50% of the granule; type 2, solid core occupying
less than 50% of the granule; type 3, fragmented core; or
type 4, empty granule/no visible core [34,35].
Determination of platelet size and distribution by
flow cytometry
Integrin αIIbβ3 expression was measured in whole blood
by incubation with fluorescein isothiocyanate (FITC)-conju-
gated anti-CD41/61 monoclonal antibody (BD Biosciences,
Bergen County, NJ, USA) for 15 minutes. Forward and side
scatter and percentage platelets to total cell number were
analyzed using FACSDiva version 6.1.2 software (BD Biosci-
ences) on a FACSCalibur flow cytometer (BD Biosciences).
Platelet isolation for protein analysis
Peripheral blood samples were obtained from the retro-
orbital sinus (anticoagulated with ACD pH6.5 (7 mM cit-
ric acid; 93 mM sodium citrate; 140 mM dextrose); 9:1).
PRP was obtained as described above. Platelets were ob-
tained by PRP centrifugation at 2,300 rpm for 10 minutesand washed twice with ACD pH6.5. For proteomic pur-
poses, PRP of littermates with the same genotype was
pooled to yield sufficient protein contents to prepare the
platelet pellets.
Determination of serotonin levels in platelets and serum
Serum was obtained from blood coagulated for 30 minutes
at 37°C in glass cuvettes followed by centrifugation at
2,300 rpm for 10 minutes. Serotonin content of platelets,
isolated as mentioned above, and serum was calculated
using the serotonin research ELISA (Labor Diagnostika
Nord, Nordhorn, Germany) according to the protocol of
the manufacturer (n = 8 mice/genotype).Two dimensional-differential gel electrophoresis
(2D-DiGE)
Platelet pellets (n = 4 samples/genotype) were lysed in
DiGE lysis buffer containing 7 M urea, 2 M thiourea, 4%
CHAPS and 30 mM Tris pH 8.5 and a complete protease
inhibitor cocktail (Roche Applied Science, Penzberg,
Germany). The samples were purified with the 2D
Clean-Up Kit (GE Healthcare, Buckinghamshire, UK)
and the concentration was determined using the 2D
Quant Kit (GE Healthcare) according to the manufac-
turer’s guidelines. Proteins were labeled with carbocya-
nine (Cy) dyes as previously described [31]. Briefly, 50
μg of each sample was labeled with 200 pmol of Cy3 or
Cy5. To avoid possible bias due to labeling efficiency,
two samples of each genotype were labeled with Cy3
and the other two with Cy5. The internal standard con-
sisting of a pool of all samples was labeled with Cy2
allowing a quantitative comparison for a protein of two
samples resolved on the same gel (ratio Cy3/Cy2 and
Cy5/Cy2) and a quantitative comparison of multiple
gels. Mixtures of Cy3-, Cy5- and Cy2-labeled samples
were diluted 1:1 with lysis buffer containing 0.5% IPG
buffer (pH 4 to 7) and 1.3% dithiothreitol (DTT) and
applied by cup loading on rehydrated IPG strips (pH 4
to 7, 18 cm). The first dimension was carried out in an
IPGphor system (GE Healthcare) with the following
conditions: 1 h 30 minutes at 150 V, 2 h at 500 V, 5 h at
1,000 V, 3 h at 8,000 V in gradient and 5 h at 8,000 V.
IPG strips were subsequently incubated in equilibra-
tion buffer (6 M urea, 30% glycerol, 2% SDS and 50
mM Tris pH 8.5) supplemented with 65 mM DTT for
20 minutes and followed by incubation in equilibration
buffer supplemented with 200 mM iodoacetamide and
0.02% bromophenol blue for 20 minutes. The second
dimension was performed on 11% polyacrylamide gels
on the Hoefer DALT vertical system (GE Healthcare).
Visualization and analysis of the images as well as the
identification of differentially expressed proteins were
executed as described previously [31].
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Platelet pellets were resolved in lysis buffer (1% Igepal;
0,015% DTT; 1 mM ethylene diamine tetraacetic acid
(EDTA) in PBS supplemented with a complete protease
inhibitor cocktail) (Roche Applied Science). Protein con-
centration of the platelet and brain lysates was quantified
with a bicinchoninic acid (BCA) protein assay (Thermo
Scientific, Rockford, IL, USA). Depending on the molecu-
lar weight of the protein of interest, 25 μg of platelet or
brain lysates was loaded on a 10% Bis-Tris gel (Bio-Rad,
Hercules, CA, USA) or 3 to 8% Tris-Acetate gel (Life tech-
nologies, Paisley, UK). Proteins were transferred to Protan
Nitrocellulose membrane (Schleicher & Schuell, Dassel,
Germany) and incubated with antibodies against
Munc13-4 (Santa Cruz Biotechnology, Santa Cruz, CA,
USA; 1/1,000), Rab27b (homemade antibody, 1/1,000),
Calmodulin (kindly provided by Professor H Desmedt,
KU Leuven; 1/1,000), Talin-1 (Cell Signaling Technol-
ogy, Danvers, MA, USA; 1/500), Calpain-2 large sub-
unit (Cell Signaling Technology; 1/1000), Calpain-4
regulatory subunit (Santa Cruz Biotechnology; 1/
1,000), phospho-(Ser/Thr) PKA substrate antibody
(Cell Signaling Technology; 1/1,000), and actin
(Sigma-Aldrich, St Louis, MO, USA; 1/5,000), used for
normalization. Equal amounts of actin protein expres-
sion were verified after incubation with an anti-
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
antibody (Abcam, Cambridge, UK; 1/15,000). After-
wards, membranes were incubated with horseradish
peroxidase (HRP)-conjugated secondary antibody (1/
2,000; DAKO, Glostrup, Denmark) and proteins were
visualized with western blotting ECL detection reagent.
Quantification was performed using the Kodak Imager
software (Kodak, Rochester, NY, USA).
Immunoprecipitation
Per sample, 20 μl of 50% bead slurry of protein A agar-
ose beads (GE Healthcare) was used and washed twice
with PBS before use. All incubations were performed
at 4°C on a mechanical rotator. Prior to immunopre-
cipitation, pre-clearing of the platelet or brain sample
was performed as follows. Protein A agarose beads
were incubated with rabbit serum (ImmuniBioScience,
Mukiltoe, WA, USA) for 1 h after which 60 μg of plate-
let or brain sample was added for 1 h. The immunopre-
cipitation was subsequently performed with the pre-cleared
supernatant by adding phospho-(Ser/Thr) PKA substrate
antibody (Cell signaling technology; 1/100) for overnight in-
cubation, followed by an additional 2 h incubation with
protein A agarose beads. Beads were washed five times with
PBS and proteins were harvested by resuspension of the
beads in sample buffer (50 mM Tris–HCl pH 7; 10%
glycerol; 2% SDS; bromophenol blue) compatible with im-
munoblot analysis.Peptidomics
Platelets were isolated as described above with modification
of the final wash buffer, which was now replaced by PBS.
The procedure for processing the platelet pellets (n = 5
mice/genotype) for mass spectrometry analysis was per-
formed as reported [36]. DeCyder MS 2.0 (GE Healthcare)
is a differential analysis software tool that also allows for
easy visualization of liquid chromatography mass spectrom-
etry (LC-MS) runs by creating artificial two-dimensional
maps with the m/z values and retention times in the first
and second dimension, respectively. Time alignment, inten-
sity normalization and statistics were performed using this
software. Peptides were identified in additional LC-MS/MS
runs of the pooled samples as reported in [36] using LC
quadrupole time-of-flight (Q-TOF) MS.
Statistical analysis
Data are presented as mean ± standard error of the
mean (SEM). Significance of differences was analyzed
using (where appropriate) the two-tailed t-test, t-test
for single means, Mann–Whitney U-test (MWU) or
Pearson Chi-square test using Statistica version 9.0 (Stat-
Soft Inc., Tulsa, OK, USA). All statistical tests were per-
formed with 0.05 as the α-level of significance (*P <0.05,
**P <0.01 and ***P <0.001).
Results
Nbea+/− mice have normal platelet counts and MPV
Heterozygous Nbea mice had a similar platelet count
(n = 10/genotype; two-tailed t-test, P = 0.20 (Table 1)
and MPV (n = 10/genotype; two-tailed t-test, P = 0.58)
(Table 1) compared to wild-type mice. The normal plate-
let size, distribution and count was confirmed by means
of flow cytometry analysis, as no differences could be de-
tected in forward and side scatter or in percentage
CD41/61-positive platelets relative to the total blood
cell-number (n = 10/genotype; two-tailed t-test, P =
0.83, P = 0.34 and P = 0.10, respectively) (Table 1).
Abnormal dense granules in platelets of Nbea+/− mice
The ultrastructure of the platelets of Nbea+/− mice (n =
200 platelets/genotype) was assessed to detect previously
described alterations in dense granule cores as described
for a patient haploinsufficient for NBEA [24] (Figure 1A).
The number of dense granules per platelet was similar for
Nbea+/− and Nbea+/+ mice (MWU, P = 0.94) (Table 1).
However, the total surface area within the limiting mem-
brane of the dense granules of platelets of Nbea+/− mice
was significantly reduced (MWU, P <0.001) (Table 1,
Figure 1), due to a reduced surface area of the halo sur-
rounding the dense-core (MWU, P = 0.001) (Table 1).
Based on the appearance of the dense-core, dense granules
were subdivided into 4 different types according to Weiss
et al. [35]. No significant difference between genotypes
Table 1 Morphological and functional characteristics of
blood platelets haploinsufficient for Neurobeachin
Nbea+/+ Nbea+/− P
Platelet count (103/μl) 943.6 ± 41.9 864.9 ± 42.2 0.20
Mean platelet volume (fL) 6.52 ± 0.11 6.61 ± 0.12 0.58
Flow cytometry
Forward scatter (AU) 13,683.3 ± 667.3 13,853.8 ± 255.9 0.83
Side scatter (AU) 1,038.5 ± 21.5 1,012.4 ± 13.3 0.34
Platelets/cell total (%) 9.88 ± 0.53 8.46 ± 0.57 0.10
Dense granules
Number/platelet 0.445 ± 0.028 0.441 ± 0.028 0.94
Surface area (nm2) 18,063.1 ± 696.2 14,331.3 ± 649.7 <0.001
Dense-core area (nm2) 2,375.4 ± 251.2 1,706.4 ± 183.0 0.52
Halo area (nm2) 15,687.7 ± 654.1 12,624.9 ± 607.4 0.001
Dense granule classification
Type 1 (%) 13.4 10.6 0.73
Type 2 (%) 26.7 29.3
Type 3 (%) 1.4 1.9
Type 4 (%) 58.5 58.2
Serotonin content
Serum (ng/μl) 1.99 ± 0.25 2.21 ± 0.14 0.45
Platelets (μg/109 PLTs) 7.59 ± 1.62 6.84 ± 1.61 0.75
Aggregation (amplitude %)
Collagen (5 μg/ml) 54.4 ± 5.7 52.8 ± 3.8 0.82
ATP secretion (μM)
Collagen (5 μg/ml) 1.58 ± 0.41 1.71 ± 0.67 0.87
Platelet count and size were investigated in 10 mice/genotype. Dense
granule morphology (MWU test) and classification was analyzed in 200
platelets/genotype. Dense granule classification was based on the study by
Weiss et al. [35] and the total amount of dense granules counted per
genotype was set at 100% yielding the above-mentioned separate percent-
age per dense granules type. The distribution of the dense granules into
the classification types was compared between Nbea+/− and Nbea+/+ mice
using the Pearson Chi-square test. Serotonin content was measured in
eight mice/genotype. Platelet function was assessed in four mice/geno-
type. ATP secretion and aggregation were measured for 5 minutes after
collagen stimulation. Unless stated otherwise, parameters were compared
between genotypes using the two-tailed t-test. Data are represented as
mean ± standard error of the mean. AU, arbitrary units; PLT, platelet.
Figure 1 Reduced total surface area of dense granules due to a
decrease in surface area of the halo in platelets of Nbea+/−
mice. (A) Electron microscopic view of a blood platelet of
Nbea+/+ and Nbea+/− mice. Dense granules are indicated with
black arrows. (B) Distribution of dense granule number according
to their surface area. Dense granules of platelets of Nbea+/− mice
were significantly smaller than dense granules of platelets of
Nbea+/+ mice (n = 200 platelets/genotype).
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in platelets (Pearson Chi-square test, P = 0.73) (Table 1).Normal serotonin levels in heterozygous Nbea mice
Serotonin secreted from enterochromaffin cells enters
the blood stream where it is actively taken up by plate-
lets and stored in dense granules [37]. Platelet and
serum serotonin levels were measured, but no signifi-
cant difference could be detected between Nbea+/+
mice and Nbea+/− mice (n = 8 mice/genotype; two-
tailed t-test, P = 0.75 and P = 0.45, respectively)
(Table 1).Subtle changes in platelet function in Nbea+/− mice
Platelet function was measured by the ATP secretion
and aggregation test. In line with measurements of com-
parable serotonin levels, dense granules from wild-type
and heterozygous Nbea mice secrete similar levels of
ATP upon collagen stimulation (n = 4 mice/genotype;
two-tailed t-test, P = 0.87) (Table 1).
Collagen binds to its glycoprotein receptors on the
plasma membrane of platelets, resulting in the activation
of phospholipase γ2 leading to an increase of intracellular
Ca2+. The subsequent critical event is the reorganization
of the actin cytoskeleton underlying filopodia and lamello-
podia formation. This process is the essence of the platelet
shape change which precedes platelet aggregation [38].
Although platelet aggregation after collagen stimulation
was normal for Nbea+/− mice (n = 4 mice/genotype; two-
tailed t-test, P = 0.82) (Table 1), they consistently
presented with a more pronounced shape change after
collagen activation (Figure 2).
Figure 2 More pronounced shape change of platelets of Nbea+/−
mice upon collagen stimulation. Collagen was added to wild-type
and heterozygous platelet-rich plasma samples, respectively, at time
points indicated by the blue and black arrows. Upon collagen stimula-
tion, ATP secretion and aggregation were measured in the following 5
minutes. Trace 1 and 3 visualize the aggregation of platelets from
Nbea+/+ and Nbea+/− mice, respectively. The shape change preceding
the aggregation is indicated with a black rectangle. All replication ex-
periments show a similar, more pronounced shape change for Nbea+/−
mice. Traces 2 and 4 are the visualization of the ATP secretion of plate-
lets of Nbea+/+ and Nbea+/− mice, respectively (n = 4 mice/genotype).
Quantification of total ATP secretion was done after corrections for
background values (ATP secretion in platelet-poor plasma). Though it
seems that there were differences between the ATP secretion curves
for Nbea+/+ and Nbea+/− mice in this experiment, quantification of ATP
secretion values after correction for backgrounds in triplicate experi-
ments, as shown in Table 1, showed no significant differences
between genotypes.
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To identify proteins differentially expressed in platelets of
Nbea+/− mice, a 2D-DiGE experiment was performed (n =
4 samples/genotype). A representative gel of the protein
profile of platelets of Nbea+/+ and Nbea+/− mice is shown
in Additional file 1. Each gel contained at least 1,432 genu-
ine protein spots, based on a manual verification of the
three-dimensional profile characteristics. Only proteins
present in at least 50% of the gel images were included for
statistical analysis. A difference in expression was found for
a total of 21 proteins, with 10 proteins having a reduced
expression level and 11 proteins with an increased expres-
sion level in platelets of Nbea+/− mice compared to plate-
lets of Nbea+/+ mice (Additional file 1). Post-translationalmodifications probably explain the different positions of
the identified proteins on the gel. However, no significant
differences in expression level were observed, as the
change in these 21 proteins was never greater than 1.3-
fold, the reliable threshold for differential expression in
2D-DiGE experiments.
In addition, western blot was performed for several pro-
teins related to dense granule biogenesis and secretion.
The actin protein expression in platelets of Nbea+/− mice
was comparable with the actin levels in Nbea+/+ mice, al-
though contradictory findings are reported with regard to
altered total actin levels in Nbea−/− mice [22,23,39,40].
Additional western blot analysis confirmed no differences
in actin protein expression levels, when normalized to the
GAPDH content, between Nbea+/+ and Nbea+/− mice (n =
4 samples/genotype; two-tailed t-test, P = 0.56) (Figure 3A).
Therefore, total actin level can be used as an internal con-
trol for western blot analysis. The expression of Munc13-4,
Rab27b and Calmodulin after actin normalization did not
significantly differ between Nbea+/+ and Nbea+/− mice (n =
4 samples/genotype; two-tailed t-test; Munc13-4, P = 0.77;
Rab27b, P = 0.51; Calmodulin, P = 0.81) (Figure 3B).
Differential peptidomics of platelets of Nbea+/− mice
Platelets contain a wide variety of peptides as well as pro-
teins [41]. The peptide content of platelets of wild-type and
heterozygous Nbea mice were compared by LC Q-TOF
MS. Only peptides that were sufficiently abundant, well-
aligned in time and present in at least three out of five sam-
ples were considered for statistical analysis. This resulted in
approximately twenty differential peptides of which six
could be identified (n = 5 mice/genotype) (Table 2). Quanti-
fication revealed significantly lower levels of six peptides,
namely Thymosin β4 (full length and fragments containing
amino acids (AA) 1 to 18 and 19 to 43; two-tailed t-test,
P = 0.048), full length Thymosin β10 (two-tailed t-test, P =
0.020), Talin-1 (peptide containing AA 449 to 465; two-
tailed t-test, P = 0.032) and the C-terminal part of
Transgelin-2 (peptide containing AA 178 to 199; two-tailed
t-test, P = 0.028). Interestingly, all these proteins are de-
scribed as modulators of the actin cytoskeleton.
Altered cleavage of Talin-1 and altered phosphorylation
of Calpain-2 in Nbea+/− mice
The peptide identified as Talin-1 (AA 449–465) is most
likely a degradation product as Talin-1 is a high-molecular-
weight protein of 270 kDa. Talin-1 consists of two domains,
a head domain (49 kDa) and a rod domain (220 kDa) joined
by a linker region containing a Calpain-2 (m-Calpain)
cleavage site [43,44]. Western blot was performed for Talin-
1 to assess the expression level and cleavage in platelets of
Nbea+/− mice (n = 4 samples/genotype). The expression
level of full-length Talin-1 was slightly increased in platelets
of Nbea+/− mice but the difference was not significant (two-
Figure 3 Normal expression of actin and the proteins involved in dense granule formation and secretion in platelets of Nbea+/− mice.
(A) Western blot analysis detected no changes in the total actin levels in platelets of Nbea+/− mice compared to Nbea+/+ mice. Actin expression
was normalized to the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) content and the expression in platelets of wild-type mice was set at
100% (n = 4/genotype). (B) The total amount of Munc13-4, Rab27b and Calmodulin was unaltered in platelets of Nbea+/− mice. Protein levels
were normalized to actin and the expression level in platelets of Nbea+/+ mice was set at 100% (n = 4 samples/genotype).
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http://www.molecularautism.com/content/4/1/43tailed t-test, P = 0.35) (Figure 4A). However, the presence
of cleavage products of Talin-1 was markedly reduced in
platelets of Nbea+/− mice compared to Nbea+/+ mice, as the
expression of both the rod and head domain was signifi-
cantly decreased (two-tailed t-test, P = 0.018 and P = 0.002,
respectively) (Figure 4A). To extrapolate these findings to
brain, Talin-1 cleavage was studied in total brain lysates
(n = 5 samples/genotype). As with platelet samples,
the presence of the head domain was significantly reduced
in the brain tissue of Nbea+/− mice compared to Nbea+/+
mice (t-test for single means, P = 0.04) (Figure 4B) and
















Talin-1 P26039 269.8 TLN 1829.88 LPAIMR
(449–465)
Transgelin-2 Q9WVA4 22.4 TAGLN2 2295.06 MGTNRGAS
(178–199)
Thymosin β10 Q6ZWY8 5.03 TYB10 4933.43 ADKPDMG
TQEKNT
The molecular weight (MW) is the MW of the precursor. A positive WT/HET ratio ind
identified peptide is indicated between brackets with the numbers corresponding t
two-tailed t-test (n = 5 mice/genotype).expression (t-test for single means, P = 0.55). There were
several unsuccessful attempts to quantify the presence of
the rod domain of Talin-1, due to a low signal-to-noise ratio
for this domain. However, the reduced ratio of the head do-
main versus full-lengthTalin-1 indicates that in the brain tis-
sue of Nbea+/− mice the cleavage of Talin-1 is also reduced.
The protease responsible for the cleavage, Calpain-2, is a
large catalytic subunit which forms a heterodimer with a
regulatory subunit, Calpain-4 (Calpain small subunit 1)
[45]. In order to investigate the reduced cleavage of Talin-
1, western blot for Calpain-2 and -4 was performed and
indicated similar expression levels of Calpain-2 and -4 in+/− mice
de sequence Modification Identification WT/HET
ratio
P














QAGMTGYGMPRQIL MS/MS and [41] 2.1505 0.028
EIASFDKAKLKKTE Acetylation MS/MS 2.0944 0.020
LPTKETIQEKRSEIS
icates a decrease in intensity in platelets of Nbea+/− mice. The length of the
o the respective amino acids. Genotype differences were tested using the
Figure 4 Altered processing of Talin-1 and altered phosphorylation of Calpain-2. (A, B) As well as the normal levels of full-length Talin-1,
the presence of the cleavage products (head and/or rod domain) was significantly reduced in platelets (A) and in brain tissue (B) of
Nbea+/− mice (n = 4 samples/genotype). (C, D) Western blots of Calpain-2 and -4, responsible for Talin-1 cleavage, indicated a similar expression
of both Calpain subunits in platelets (C) and in total brain lysates (D) of Nbea+/− and Nbea+/+ mice (n = 4 samples/genotype and n = 3 samples/
genotype, respectively). (E) Immunoprecipitation of phospho-(Ser/Thr) protein kinase A (PKA) substrates in platelets followed by Calpain-2 western
blot revealed an increase in PKA-mediated phosphorylation of Calpain-2 (n = 6 samples/genotype). (F) Immunoprecipitation of phospho-(Ser/Thr)
PKA substrates in total brain tissue followed by Calpain-2 western blot showed a decrease in PKA-mediated phosphorylation of Calpain-2
(n = 4 samples/genotype).
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0.31 and P = 0.67, respectively) (Figure 4C) and in total
brain lysates (n = 3 samples/genotype; t-test for single
means, P = 0.34 and P = 0.92, respectively) (Figure 4D) of
wild-type and heterozygous Nbea mice.
The activity of Calpain-2 is negatively correlated with its
phosphorylation status at a PKA consensus site [46,47]. As
Nbea is an AKAP protein, Nbea haploinsufficiency might
result in defects in the sequestering of inactive PKA and
compartmentalization of PKA, leading to altered PKA ac-
tivity in different subcellular locations [48]. Therefore, the
phosphorylation status of Calpain-2 in resting platelets and
brain was examined. The lack of an anti-phosphoCalpain-2
antibody specific for PKA phosphorylation was overcome
by performing immunoprecipitation with a phospho-(Ser/
Thr) PKA substrate antibody detecting proteins containinga phosphorylated serine or threonine with an arginine at
the -3 position, followed by western blot with Calpain-2
antibody. The level of phosphorylated Calpain-2 was sig-
nificantly increased in platelets of Nbea+/− mice with an
average ratio of 2.8 (n = 6 samples/genotype; two-tailed t-
test, P = 0.044) (Figure 4E). In contrast, the level of phos-
phorylated Calpain-2 in brain tissue of Nbea+/− mice was
significantly decreased by a factor of 2.86 (n = 4 samples/
genotype; t-test for single means, P = 0.001) (Figure 4F).
To examine whether Nbea haploinsufficiency has a more
general effect on PKA-dependent phosphorylation, western
blot of platelet lysate with the phospho-(Ser/Thr) PKA
substrate antibody was performed. Several phosphorylated
proteins were detected in resting platelets of Nbea+/+ and
Nbea+/− mice and the phosphorylation of the three pro-
teins with the highest molecular weight was significantly
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for single means, band 1, P = 0.042; band 2, P = 0.027;
band 3, P = 0.010) (Figure 5A). Additionally, the phos-
phorylation of two other proteins was significantly re-
duced (t-test for single means, band 7, P <0.001 and band
8, P <0.001) whereas the phosphorylation of proteins 4 to
6 was unaltered (t-test for single means, P = 0.44, P = 0.30
and P = 0.62, respectively) (Figure 5A). The same study
was performed in brain tissue, which rendered several
phosphorylated proteins. The phosphorylation of band 4,
6, 9 and 10 was significantly reduced in brain tissue of
Nbea+/− mice (n = 5 samples/genotype; t-test for single
means, band 4, P = 0.047; band 6, P = 0.003; band 9, P =
0.009; band 10, P = 0.024) (Figure 5B).Figure 5 Abnormal Protein kinase A (PKA) phosphorylation pattern in
revealed several changes in phosphorylation levels of proteins in resting pl
levels were first calculated within a litter, followed by t-test for single mean
cant differences between Nbea+/+ and Nbea+/− mice. (A) In resting platele
cantly higher phosphorylation status. The following three bands had an un
significantly reduced phosphorylation profile (n = 4 samples/genotype). (B)
pattern of brain tissue, which were used for quantification. Image analysis r
proteins in brain tissue of Nbea+/− mice (n = 5 samples/genotype).Discussion
In this study we have confirmed a causal link between
Nbea haploinsufficiency and abnormal granule morph-
ology, similar to our previous observation in ASD patients
[24]. Dense granules of Nbea+/− platelets were significantly
smaller and showed a more pronounced shape change
than Nbea+/+ platelets. However, none of the 1,432 pro-
teins identified in a proteomic screen was differentially
expressed. Differential peptidomics of platelets did identify
four actin-interacting peptides with a reduced presence in
platelets of Nbea+/− mice. Validation of the peptidomic
screen revealed reduced cleavage of Talin-1, most likely
due to increased phosphorylation of Calpain-2 by PKA.
The reduced cleavage of Talin-1 was confirmed in Nbea+/−Nbea+/− mice. Visualization of proteins phosphorylated by PKA
atelets (A) and brain lysates (B) of Nbea+/− mice. Phosphorylation
s, with the mean of wild-type samples being 100%, to detect signifi-
ts the three proteins with the highest molecular weight had a signifi-
altered phosphorylation level whereas the last two bands had a
Two different exposure times are shown for the PKA phosphorylation
evealed a significant decrease in phosphorylation level of four different
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creased. The importance of Nbea as a regulator of PKA ac-
tivity was further substantiated, as haploinsufficiency of
Nbea positively and negatively affects PKA-mediated phos-
phorylation of a multitude of proteins in resting platelets
and in brain.
Normal serotonin levels were detected in platelets and
serum of Nbea+/− mice, which is consistent with the simi-
lar amount of dense granules per platelet in Nbea+/+ and
Nbea+/− mice as serotonin is taken up by platelets and
stored in the dense granules [37]. Hyperserotonemia is
one of the few biochemical anomalies reported in ASD pa-
tients and several possible causes have been suggested,
such as increased synthesis or altered release of serotonin
from enterochromaffin cells [49,50]. However, only 30% of
ASD patients have been classified as being hyperserotone-
mic and increased levels of serotonin have also been de-
tected in relatives of ASD patients [30,51]. These findings
highlight the controversy regarding hyperserotonemia as a
biomarker for ASD.
Several lines of evidence point to alterations in the cyto-
skeleton of platelets of Nbea+/− mice. First, an increased
shape change upon collagen stimulation was observed for
platelets of Nbea+/− mice. Interestingly, platelets from pa-
tients with a dense granule secretion defect also presented
with a more pronounced shape change [31]. A similar
shape change was noticed in platelets of patients with Du-
chenne muscular dystrophy, a disease characterized by a
disturbed cytoskeletal organization [52]. Second, all pep-
tides that have a significantly different level in platelets of
Nbea+/− mice are actin-interacting peptides. Transgelin-2,
also named SMβ22, was identified as an actin-associated
protein with an unknown function [53]. Thymosin β4 and
β10 are the main intracellular G-actin sequestering pep-
tides present in most mammalian cells. Binding of Thymo-
sin β to G-actin prevents the polymerization to F-actin and
reduced levels of Thymosin β4 and β10 lead to excessive
formation of F-actin [54]. A decreased presence of Thymo-
sin β4 and β10 in platelets of Nbea+/− mice might be indi-
cative for a decreased expression in neurons as well. This
could contribute to the excessive F-actin clusters detected
in the soma, dendritic shafts and axons of hippocampal
neuronal cultures of Nbea−/− mice and in the soma of cor-
tical neurons of Nbea+/− mice, although the exact mechan-
ism remains to be determined [22]. Of note, a proteomic
study using platelets from patients with a dense granule se-
cretion defect also revealed actin-binding proteins as the
major change in differentially expressed proteins compared
to control platelets [31].
Multiple F-actin binding sites have been identified in
Talin-1, both in the head and rod domain [55,56]. The
peptide of Talin-1 identified in the peptidomic screen is
likely to be a degradation product of the rod domain. The
diminished presence of this peptide in platelets of Nbea+/−mice correlates with the reduced presence of the rod do-
main detected on western blot. Talin-1 is cleaved by
Calpain-2 after amino acid 432, yielding the head and rod
domain of Talin-1 [44]. Calpain-2 activity is regulated by
phosphorylation of PKA; more specifically, phosphoryl-
ation of Ser369 or Thr370 results in decreased activity
[46,47]. The observed increase in PKA-specific phosphor-
ylation of Calpain-2 is therefore a likely cause of the re-
duced cleavage of Talin-1 in blood platelets.
It is known that the F3 subdomain in the head domain
of Talin-1 interacts with the cytoplasmic tail of β-integrin
during the platelet activation process [57]. Therefore, alter-
ations in platelet function might be expected based on the
reduced presence of the head domain of Talin-1. However,
in contrast to the conditional-knockout mouse models
generated to study the molecular function of Talin-1, no
complete ablation of Talin-1 was detected in platelets
of Nbea+/− mice. Of note is the finding that heterozy-
gous conditional Talin-1-knockout mouse models do
not present alterations in platelet function [58].
In Wistar rats, Talin is detected at the membranes of
granules and dense compartments in the megakaryocytes
[59,60]. Wistar Furth rats, a rat model with abnormal
thrombocytopoietic phenotype associated with morpho-
logically aberrant megakaryocytes lack these dense com-
partments. It is hypothesized that the lack of cytoskeletal
proteins such as Talin may be responsible for the absence
of the dense compartments in megakaryocytes of Wistar
Furth rats. Therefore, it is possible that the observed alter-
ations in Talin-1 in Nbea+/− platelets contribute to the
morphological differences of dense granules resulting in
the reduced size of these dense granules.
Decreased cleavage of Talin-1 was also observed in
total brain of Nbea+/− mice. However, PKA-mediated
phosphorylation of Calpain-2 was decreased, leading to
increased activity, in contrast to blood platelets. A pos-
sible explanation for this discrepancy between platelets
and brain tissue is that platelets represent a pure cell
population, whereas the brain is a mixed-cell popula-
tion. Therefore, it is possible that cells with reduced
phosphorylation of Calpain-2 are not the cells with high
Talin-1 expression. For instance, the brain tissue con-
sists of both excitatory and inhibitory neurons and earl-
ier studies using neuronal cultures derived from either
adult Nbea+/− mice or E18 Nbea−/− mice revealed an
imbalance in excitatory and inhibitory signaling with a
more affected inhibitory neurotransmission [22,23,39].
Likewise, the phosphorylation status of Calpain-2 might
be influenced by the excitatory/inhibitory imbalance
present in the brain of Nbea+/− mice. In addition, the
expression level of Nbea varies in different brain regions
[16], which is likely to contribute to the alterations in
PKA mediated phosphorylation on Calpain-2 upon
Nbea haploinsufficiency.
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line with the reported increase in PKA-mediated phos-
phorylation of the cAMP response element-binding pro-
tein (CREB) in a neuroendocrine cell line after knockdown
of Nbea, and indirectly, the increased level of brain-derived
neurotrophic factor (BDNF), a target of phospho-CREB, in
Nbea+/− mice [40]. As well as Calpain-2, the phosphoryl-
ation status of other proteins is affected in Nbea+/−
mice, as indicated by the increased or decreased inten-
sity of several proteins detected in a western blot of
lysates of resting platelets or brain tissue with anti-
phospho-(Ser/Thr) PKA substrate antibody. Although
the alterations in PKA-mediated phosphorylation in
total brain tissue from Nbea+/− mice are more subtle,
this might also be the result of the mixed-cell popula-
tion and variable Nbea expression levels. The concur-
rence of increased, unaltered and decreased PKA
phosphorylation of different proteins caused by Nbea
haploinsufficiency can be explained by the compart-
mentalizing role of AKAPs. Because of its AKAP do-
main, Nbea belongs to the AKAP family of proteins,
which is known to scaffold PKA near its target proteins
in a distinct subcellular compartment. Different AKAPs
lead to different PKA compartmentalizations [48]. Hap-
loinsufficiency of Nbea will lead to an altered subcellu-
lar distribution of PKA, which will cause a higher, lower
or unchanged PKA-mediated phosphorylation of target
proteins, depending on their subcellular presence. With a
continuously expanding list of ASD candidate genes, there
is increasing interest in signaling pathways linking ASD
genetics with biological functions, such as growth and
neurite outgrowth of developing neurons and synaptic
function [61,62]. There is ample genetic evidence for the
involvement of AKAPs in the etiology of ASD, and pro-
teins encoded by 10 ASD-linked AKAP genes were shown
to functionally integrate signaling cascades within and be-
tween several biological functions [63]. Haploinsufficiency
of NBEA, one of the 10 ASD-linked AKAP genes, is
thereby suggested to affect multiple pathways, most likely
via the pleiotropic effect of altered PKA activity.
Conclusions
The characterization of platelets of Nbea+/− mice provides
evidence for a causal relationship between NBEA haploin-
sufficiency in the patient and abnormal platelet morph-
ology. Furthermore, the impaired cleavage of Talin-1,
increased phosphorylation of Calpain-2, and an altered
PKA-related phosphorylation fingerprint, emphasizes the
importance of the AKAP domain of Nbea for its function.
Spatiotemporal control of PKA activity appears to be an
important physiological function of Nbea. These findings
highlight that alterations in the phosphorylation status of
proteins might contribute to the pathogenesis of ASD in at
least a subgroup of patients.Additional file
Additional file 1: Figure S1. The protein content of Nbea+/− mice
contained 21 differentially expressed proteins compared to Nbea+/+ mice,
A representative gel of the protein profile of platelets of Nbea+/+ and
Nbea+/− mice after two dimensional-differential gel electrophoresis
(2D-DiGE) is shown.
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